About FMI Technologies, Inc.

FMI Technologies, Inc. (“FMI”) has developed an ultra high resolution diagnostic imaging technology that can be combined with drugs and molecular tracers for early detection and monitoring of neurodegenerative disorders.  FMI’s PET/CT/SPECT system offers a superior and more cost-effective solution that enables advanced therapy and possible cures for Alzheimer’s disease, Vascular Dementia, Parkinson’s disease and other dementias.  In addition, its unique Fused Multimodality Imaging will offer the data critical to earlier physician diagnosis of stroke, and head and neck cancers than are possible with current technology. FMI’s mantra is “Drugs need Imaging and Imaging needs Drugs” for early asymptomatic diagnostics and personalized medicine.

PET/CT/SPECT images are combined, or "fused," to provide information as to the sensitivity and specificity for the type of cancer present, three dimensional information as to the physical location of the cancer and reference information for doctors to plan stereo-tactic biopsy, minimally invasive surgery and image guided therapy.

Technology

FMI systems are custom designed for specific diseases combining multiple common detection modalities – both structural and functional imaging (PET+CT, PET+CT+SPECT).  FMI currently has one product offering, the ScintiStar™ Neuro , which provides advanced detection and image guided therapy for neurodegenerative diseases, stroke, and brain tumors.

Structural imaging provides information about the shape, position or volume of brain tissue.

Functional imaging reveals how well cells in various brain regions are working by showing how actively the cells use sugar or oxygen and blood flow.

The technology breakthrough that FMI offers rests in its proprietary method for blending structural and functional imaging into a diagnostic tool that is 20%-25% of the cost of any single, currently-available alternative.  In fact, the ScintiStar™ Neuro system is a portable, high-resolution brain imaging system that provides anatomical and molecular images.  These features allow for quantitative diagnostic measures of brain function and anatomy and feedback for therapy planning and monitoring.

The ScintiStar™ Neuro PET/CT/SPECT imaging systems significant improvement over current wholebody PET, CT, and SPECT systems

• Improved spatial resolution (3X-4X) resulting in clearer image quality and improved quantification of molecular function.
• Improved sensitivity (2X- 3X) in the detection of gamma rays from respective imaging probes.
• Developed low dose CT imaging technology for 10 to 100 times lower dose X-ray/CT imaging
• Portable and 20% the size of whole body systems with self shielding.